<DOC>
	<DOCNO>NCT00046865</DOCNO>
	<brief_summary>RATIONALE : Acupressure may help reduce prevent nausea patient undergoing chemotherapy . It yet know whether acupressure plus standard care nausea effective standard care alone nausea woman receive chemotherapy breast cancer . PURPOSE : Randomized phase III trial determine effectiveness acupressure treat nausea woman receive combination chemotherapy breast cancer .</brief_summary>
	<brief_title>Acupressure Treating Nausea Women Receiving Combination Chemotherapy Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare nausea experience intensity woman breast cancer receive one three combination therapy regimens treated standard nausea care plus acupressure vs standard nausea care alone . - Compare quality life , presence anxiety , functional status patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord chemotherapy regimen ( doxorubicin cyclophosphamide v doxorubicin , cyclophosphamide , fluorouracil v doxorubicin paclitaxel docetaxel v fluorouracil , epirubicin , cyclophosphamide ) treatment set . Patients randomize 1 3 arm . - Arm I : Patients receive active acupressure plus usual nausea care second third course chemotherapy . Acupressure apply specific site morning whenever nausea experience 3-6 minute . - Arm II : Patients receive placebo acupressure plus usual nausea care second third course chemotherapy . Acupressure apply arm I except non-specific site . - Arm III : Patients receive usual nausea care second third course chemotherapy . All patient complete daily log second third course chemotherapy . Quality life assess baseline last treatment . PROJECTED ACCRUAL : A total 244 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast cancer receive one follow combination therapy regimens : Doxorubicin cyclophosphamide without fluorouracil Doxorubicin paclitaxel docetaxel Fluorouracil , epirubicin , cyclophosphamide Must begin second third course chemotherapy Nausea intensity prior chemotherapy least 3 ( moderate ) intensity scale Morrow Assessment Nausea Emesis Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age Adult Sex Female Menopausal status Not specify Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Concurrent antiemetic allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>nausea vomit</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>